• Uni-Bio posted revenue of HK$273.8 million, down 11.7% year on year; profit fell 59% to HK$31.2 million.
• EBITDA dropped 41.9% to HK$53.5 million; gross margin slipped 0.6 percentage points to 81.3%.
• R&D expenses rose 43.2% to HK$19.5 million, on U.S. FDA submission work for Bogutai and Isavuconazonium sulfate registration.
• Bogutai revenue climbed 39.3% to HK$91.4 million; Pinup revenue sank 47.1% to HK$57.6 million after VBP repricing.
• Total equity increased 8.6% to HK$448.7 million; debt-to-equity improved to 34.9% from 40.3% at end-2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300219), on August 26, 2026, and is solely responsible for the information contained therein.